Is adverse outcome in PrP-suppression studies attributable to the loss of PrP itself, or to the mechanism used to achieve that loss?

Prion diseases are invariably fatal neurodegenerative disorders for which no disease-modifying treatment currently exists. The plausibility of therapeutic strategies aimed at reducing or eliminating the cellular prion protein PrPC rests on the foundational observation that PrPC knockout animals develop normally and remain resistant to prion infection. However, this review demonstrates that adverse outcomes reported in the PrP-suppression literature are not reliably attributable to the loss of PrPC itself, but to the specific method used to achieve that loss. Two independent case studies are examined: lentiviral shRNA knockdown of the PrP paralogue Shadoo, which produced embryonic lethality subsequently shown to be a construct-specific artifact rather than a consequence of combined PrPC/Shadoo loss; and extensive-deletion Prnp knockout lines, in which progressive neurodegeneration was traced not to PrPC absence but to inadvertent overexpression of the neighbouring gene Prnd (Doppel), a confound directly confirmed through targeted genetic rescue and absent from more precisely constructed knockout lines. Applying this distinction to the current landscape of human PrPC lowering therapeutics reveals that no published trial has yet been designed to isolate delivery-method-specific effects from target-reduction effects. This review argues that method-specific risk, not degree of PrPC reduction alone, must be treated as an independent variable in the design and evaluation of future prion suppression strategies, and proposes that future trials directly compare outcomes across delivery constructs achieving equivalent target reduction to identify such confounds prospectively.